SARS-CoV-2 genomic diversity in households highlights the challenges of sequence-based transmission inference

Authors: Emily Bendall¹, Gabriela Paz-Bailey², Gilberto A. Santiago², Christina A. Porucznik³, Joseph B. Stanford³, Melissa S. Stockwell⁴, Jazmin Duque⁵, Zuha Jeddy⁵, Vic Veguilla², Chelsea Major², Vanessa Rivera-Amill, PhD⁶, Melissa A. Rolfes², Fatimah S. Dawood², Adam S. Lauring^{1,7*}

Affiliations: ¹Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA; ² Centers for Disease Control and Prevention; ³ Division of Public Health, Department of Family and Preventive Medicine, University of Utah School of Medicine; ⁴Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, and Department of Population and Family Health, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY; ⁵Abt Associates; ⁶Ponce Health Sciences University/Ponce Research Institute; ⁷ Division of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA;

*** Corresponding Author**: Adam S. Lauring, MS2 4742C, SPC 1621, 1137 Catherine Street, Ann Arbor, MI 48109; (734) 764-7731; alauring@med.umich.edu.

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Keywords: SARS-CoV-2; genomic epidemiology; transmission; household **Running Title**: SARS-CoV-2 diversity in households **Abstract Word Count**: 200 **Main Text Word Count**: 3009 **Summary**: High depth of coverage whole genome sequencing can identify SARS-CoV-2 transmission chains in settings where there is strong epidemiologic linkage but is not reliable as a stand-alone method for transmission inference.

ABSTRACT

INTRODUCTION

and Iron Counties) and New York City [24] during August 2020 through February 2021 and

households in Utah (Salt Lake, Weber, Davis, Box Elder, Cache, Tooele, Wasatch, Summit, Utah,

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.09.22278452;](https://doi.org/10.1101/2022.08.09.22278452) this version posted August 22, 2022. The copyright holder for this preprint

 followed them with surveillance for SARS-CoV-2 infection during September 2020 through August 2021. The Communities Organized for the Prevention of Arboviruses (COPA) was expanded to include investigation of the epidemiology of COVID-19, creating the COCOVID study, and recruited households in Ponce, Puerto Rico. For C-HEaRT, household eligibility criteria included: ≥1 child aged 0-17 years, ≥75% of household members met individual level eligibility (all members if a 2- or 3-person household), one adult member was willing to complete monthly questionnaires, and adult members could communicate in English or Spanish. Individual eligibility criteria included: anticipated residence in the household for ≥3 consecutive months, and willingness to complete study surveys, weekly symptom assessments, and self-collect respiratory specimens. For COCOVID, household members were eligible if they were aged ≥1 year, slept in the house ≥4 nights per week, had no definite plans to move in the next year, and were willing and able to comply with study requirements. For both studies, written informed consent (paper or electronic) was obtained from adults (aged >18 years in C- HEaRT and >20 years in COCOVID). Parents or legal guardians of minor children provided 82 written informed consent on behalf of their children; older children (aged 12-17 years in C- HEaRT and 7–20 years in COCOVID) also provided assent to study participation. The C-HEaRT study protocol was reviewed and approved by the University of Utah Institutional Review Board (IRB) as the single IRB for all collaborators. The COCOVID study protocol was reviewed and approved by the Ponce Medical School Foundation, Inc. IRB.

Sample Collection and Testing

 Participants were asked to self-collect (or parent/guardian-collect for children) mid-turbinate nasal swabs every week, regardless of illness symptoms, and place the swabs in viral transport media. Participants were also contacted by text message or email every week to ascertain if they had COVID-19-like (CLI) or any other illness symptoms; they were asked to self-collect an additional mid-turbinate flocked nasal swab once with onset of CLI symptoms. CLI was defined as 1 or more of the following: fever or feverishness, cough, shortness of breath, sore throat, diarrhea, muscle aches, chills, or change in taste or smell. Respiratory specimens were shipped overnight to a central lab and tested using either the Quidel Lyra SARS-CoV-2 Assay or the ThermoFisher Combo Kit platform. The assays were approved under Emergency Use Authorization for the diagnosis of SARS-CoV-2 infection prior to use in this study. Test-positive infections in the same household that were first detected by RT-PCR within 14 days of each other (including those detected on the same date) were considered epidemiologically linked and likely to have resulted from within-household transmission. **SARS-CoV-2 Genomic Sequencing** SARS-CoV-2 genomic sequencing was attempted on all specimens with an RT-PCR cycle threshold (Ct) ≤30 on either the nucleocapsid protein 1 or 2 target. SARS-CoV-2 genomes were sequenced as described previously [10]. Briefly, RNA was extracted from midturbinate nasal swab specimens with the MagMax MVPII viral nucleic acid isolation kit on a Kingfisher Flex (Thermofisher) and reverse transcribed with Lunascript (NEB). We amplified SARS-CoV-2 cDNA in two pools using the ARTIC Network v3 primers and protocol. Amplicon pools were combined

in equal volumes for a given sample and purified with magnetic beads. Barcoded sequencing

 libraries were prepared using the NEBNext ARTIC SARS-CoV-2 Library Prep Kit with magnetic bead size selection. Individual barcoded sample libraries were pooled (up to 96) and sequenced on an Illumina MiSeq (v2 chemistry, 2x250 cycles).

Phylogenetic Analysis

 Consensus sequences for each household were placed on the global SARS-CoV-2 phylogenetic tree using UShER [28]. The tree versions used were from the week of 14 February 2022 and included over 7.8 million genome sequences from GISAID, GenBank, COG-UK and CNCB. The level of genomic sampling of the state or territory of each study site (Figure 1) was estimated with subsampler [10] using case data and GISAID submission data. Subtrees were initially constructed with 30 samples and then reconstructed with additional samples as needed to

Utah site and 7% [33/499 participants in 13/135 (10%) households] at the New York City site;

 during June 2020 through September 2021, cumulative incidence was 5% at the Puerto Rico site (49/1028 infections detected in 28/381 households).

 In 11 households, the consensus sequences of the virus from one or more household members differed at 1-2 positions over the nearly 30kb genome. This is not uncommon in transmission chains, particularly ones that are longer or in which the samples are collected 7-14 days apart (see Table 2 for time span). In nearly all cases, the trees from these households demonstrated linkage and/or an ancestor/descendant relationship for the viral sequences (representative trees in Figure 3, additional trees in Supplemental Figure 5). In some cases, the household lineages were phylogenetically distinct from contemporaneous local sequences (e.g., UT2, UT4). These tree structures supported transmission linkage, but low sampling of community cases makes it hard to rule out missed linkages between members of the household and the larger

 community. Indeed, there were some households in which there were sequences from the larger community included among the same branches of the within-household sequences (e.g., UT10, PR3). As above, the low genomic diversity of SARS-CoV-2 and modest sampling of community cases made it difficult to define a threshold to effectively rule in or rule out transmission. We next determined whether transmission inference could be improved by identifying iSNV that were shared among members of a household. These would manifest as polymorphic sites where the alternative allele, or mutation, is present but not fixed in the transmission chain. While there was just one household where two participants shared a minority iSNV (PR5, Figure 4), several had iSNV in at least one individual at a consensus level (i.e., frequency >0.5), but that had not yet achieved fixation (i.e., frequency >0.95). In the 15 households with indistinguishable consensus sequences, each of the two participants in households NY5 and PR5 211 shared an iSNV that was consensus level, but not fixed. In three (UT12, UT5, UT3) out of the 11 households with distinct consensus sequences (Table 2), the consensus differences were due to one or more participants having a non-reference iSNV that achieved consensus level, but not fixation. Household UT4 had two participants with consensus level iSNV (Figure 4). In household PR3, there was one site where one out of four members had a consensus level iSNV and another member had this as a fixed mutation.

DISCUSSION

ACKNOWLEDGMENTS

 We thank the participants in the C-HEaRT and COCOVID cohorts and all GISAID submitting laboratories. We acknowledge Anderson Britto for developing and suggesting the subsampler tool used to generate Figure 1.

REFERENCES

- 1. Lauring AS. Within-Host Viral Diversity: A Window into Viral Evolution. Annu Rev Virol **2020**; 7:63–81.
- 2. Kao RR, Haydon DT, Lycett SJ, Murcia PR. Supersize me: how whole-genome sequencing
- and big data are transforming epidemiology. Trends Microbiol **2014**; 22:282–291.
- 3. Lemieux JE, Siddle KJ, Shaw BM, et al. Phylogenetic analysis of SARS-CoV-2 in Boston
- highlights the impact of superspreading events. Science **2021**; 371:eabe3261.
- 4. Siddle KJ, Krasilnikova LA, Moreno GK, et al. Transmission from vaccinated individuals in a

large SARS-CoV-2 Delta variant outbreak. Cell **2022**; 185:485-492.e10.

- 5. Zeller M, Gangavarapu K, Anderson C, et al. Emergence of an early SARS-CoV-2 epidemic in the United States. Cell **2021**; 184:4939-4952.e15.
- 6. Worobey M, Pekar J, Larsen BB, et al. The emergence of SARS-CoV-2 in Europe and North America. Science **2020**; 370:564–570.
- 7. du Plessis L, McCrone JT, Zarebski AE, et al. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. Science **2021**; 371:708–712.
- 8. Candido DS, Claro IM, de Jesus JG, et al. Evolution and epidemic spread of SARS-CoV-2 in
- Brazil. Science **2020**; 369:1255–1260.
- 9. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature **2022**; 603:679–686.

- CoV-2 variant B.1.1.7 in the United States. Cell **2021**; 184:2595-2604.e13.
- 11. Valesano AL, Fitzsimmons WJ, Blair CN, et al. SARS-CoV-2 Genomic Surveillance Reveals
- Little Spread From a Large University Campus to the Surrounding Community. Open Forum
- Infect Dis **2021**; 8:ofab518.
- 12. Aggarwal D, Warne B, Jahun AS, et al. Genomic epidemiology of SARS-CoV-2 in a UK
- university identifies dynamics of transmission. Nat Commun **2022**; 13:751.
- 13. Lucey M, Macori G, Mullane N, et al. Whole-genome Sequencing to Track Severe Acute
- Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission in Nosocomial Outbreaks.
- Clin Infect Dis **2021**; 72:e727–e735.
- 14. Francis RV, Billam H, Clarke M, et al. The Impact of Real-Time Whole-Genome Sequencing
- in Controlling Healthcare-Associated SARS-CoV-2 Outbreaks. J Infect Dis **2022**; 225:10–18.
- 15. Meredith LW, Hamilton WL, Warne B, et al. Rapid implementation of SARS-CoV-2
- sequencing to investigate cases of health-care associated COVID-19: a prospective
- genomic surveillance study. Lancet Infect Dis **2020**; 20:1263–1271.
- 16. Hamilton WL, Fieldman T, Jahun A, et al. Applying prospective genomic surveillance to
- support investigation of hospital-onset COVID-19. Lancet Infect Dis **2021**; 21:916–917.
- 17. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and
- Transmission in a Skilled Nursing Facility. N Engl J Med **2020**; 382:2081–2090.

- Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High
- Attack Rate. J Clin Microbiol **2020**; 58:e02107-20.
- 19. McCrone JT, Woods RJ, Martin ET, Malosh RE, Monto AS, Lauring AS. Stochastic processes
- constrain the within and between host evolution of influenza virus. eLife **2018**; 7:e35962.
- 20. Worby CJ, Lipsitch M, Hanage WP. Shared Genomic Variants: Identification of Transmission
- Routes Using Pathogen Deep-Sequence Data. Am J Epidemiol **2017**; 186:1209–1216.
- 21. Braun KM, Moreno GK, Wagner C, et al. Acute SARS-CoV-2 infections harbor limited
- within-host diversity and transmit via tight transmission bottlenecks. PLOS Pathog **2021**; 17:e1009849.
- 22. Valesano AL, Rumfelt KE, Dimcheff DE, et al. Temporal dynamics of SARS-CoV-2 mutation
- accumulation within and across infected hosts. PLOS Pathog **2021**; 17:e1009499.
- 23. Tonkin-Hill G, Martincorena I, Amato R, et al. Patterns of within-host genetic diversity in SARS-CoV-2. eLife **2021**; 10:e66857.
- 24. Dawood FS, Porucznik CA, Veguilla V, et al. Incidence Rates, Household Infection Risk, and
- Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and
- New York City, New York. JAMA Pediatr **2022**; 176:59.

- ArXiv13033997 Q-Bio **2013**; Available at: http://arxiv.org/abs/1303.3997. Accessed 31 July
- 2020.
- 26. Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing framework
- for accurately measuring intrahost virus diversity using PrimalSeq and iVar. Genome Biol **2019**; 20:8.
- 27. De Maio N, Walker C, Borges R, Weilguny L, Slodkowicz G, Goldman N. Masking strategies
- for SARS-CoV-2 alignments. Virological. 2020; Available at:
- https://virological.org/t/masking-strategies-for-sars-cov-2-alignments/480. Accessed 10 March 2022.
- 28. Turakhia Y, Thornlow B, Hinrichs AS, et al. Ultrafast Sample placement on Existing tRees
- (UShER) enables real-time phylogenetics for the SARS-CoV-2 pandemic. Nat Genet **2021**; 53:809–816.
- 29. Walter KS, Kim E, Verma R, et al. Shared within-host SARS-CoV-2 variation in households. medRxiv **2022**; :2022.05.26.22275279.
- 30. Lythgoe KA, Hall M, Ferretti L, et al. SARS-CoV-2 within-host diversity and transmission. Science **2021**; :eabg0821.
- 31. Braun KM, Moreno GK, Buys A, et al. Viral Sequencing to Investigate Sources of SARS-CoV-
- 2 Infection in US Healthcare Personnel. Clin Infect Dis **2021**; 73:e1329–e1336.

- 32. Lindsey BB, Villabona-Arenas ChJ, Campbell F, et al. Characterising within-hospital SARS-
- CoV-2 transmission events using epidemiological and viral genomic data across two
- pandemic waves. Nat Commun **2022**; 13:671.

364 **Table 1:** Distribution of SARS-CoV-2 test-positive cases across cohorts and households

365

a total number over study period

 b only households with cases testing</sup>

positive within 14 days of each other

a Defined using nextclade, https://clades.nextstrain.org

b Defined using pango, https://cov-lineages.org/resources/pangolin.html

c Total number of pairwise unambiguous consensus differences between sequences divided by total number of sequences in a household

FIGURE LEGENDS

 colored black. The collection date for each sample is indicated. Genetic distance is represented by the bar and corresponds to one mutation.

 Fig. 4: Shared single nucleotide polymorphisms within households. Each panel shows one of the 8 households in which members shared a polymorphic site. The frequency (5-95%) of the indicated mutation (relative to the Wuhan/Hu-1 reference) is shown on the y-axis and the individual/sequence identifier is shown on the x-axis. Shared variants that did and did not lead to a consensus level difference between household members are shown as circles and diamonds, respectively. Mutations that are fixed (>95% frequency) are shown as squares. **Supplemental Figures 1-4: Phylogenetic trees of sequences from households where all participants had indistinguishable consensus sequences.** Each tree is labeled with the household identifier (NY = New York, UT = Utah, PR = Puerto Rico). The tips of household sequences are colored cyan and those from the same state or territory (2 letter abbreviation) are colored magenta. All other tips are colored black. The collection date for each sample is indicated. Genetic distance is represented by the bar and corresponds to one mutation. **Supplemental Figure 5: Phylogenetic trees of sequences from seven households where participants had distinct consensus sequences.** Each tree is labeled with the household identifier (NY = New York, UT = Utah, PR = Puerto Rico). The tips of household sequences are colored cyan and those from the same state or territory (2 letter abbreviation) are colored

- magenta. All other tips are colored black. The collection date for each sample is indicated.
- Genetic distance is represented by the bar and corresponds to one mutation.

- **Supplemental Table 1:** Submitting laboratories for GISAID sequences used in this study. GISAID
- identifiers can be found in the unedited trees in the Supplemental Dataset.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.09.22278452;](https://doi.org/10.1101/2022.08.09.22278452) this version posted August 22, 2022. The copyright holder for this preprint

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.08.09.22278452;](https://doi.org/10.1101/2022.08.09.22278452) this version posted August 22, 2022. The copyright holder for this preprint

Supplemental Figure 1

Supplemental Figure 2

NY2

Supplemental Figure 3

Supplemental Figure 4

Supplemental Figure 5

USA/Consensus_89364_threshold_0.5_quality_20/2020|OM095264.1|2020-05-01

USA/Consensus_89293_threshold_0.5_quality_20/2020|OM095258.1|2020-05-01

MT 2020-11-03

 0.6

UT 2020-11-18

MT 2020-11-03

USA/Consensus_89364_threshold_0.5_quality_20/2020|OM095264.1|2020-05-01

USA/Consensus_89293_threshold_0.5_quality_20/2020|OM095258.1|2020-05-01

UT 2020-11-30 UT 2020-11-30 UT 2020-11-30 **MT 2020-10-26**

AZ 2020-11-02

MT 2020-10-05

UT 2020-11-30

UT 2020-11-30 UT 2020-11-30 UT 2020-09-06

 $MT 2020-10-07$

UT 2020-11-18

UT 2020-11-30 UT 2020-11-30

UT 2020-11-30 UT 2020-11-30

UT 2020-11-30 UT 2020-11-30

MT 2020-10-07

UT 2020-09-06

MT 2020-10-26

MT 2020-10-05

AZ 2020-11-02

CO 2021-03-08 IN 2021-03-15 CO 2021-03-26 OR 2021-01-27 CO 2021-04-25 OR 2021-01-27 CO 2021-03-11 AZ 2021-02-18 CO 2021-02-25 WI 2021-03-01 N8KCTLE5 | 2021-03-01 UT 2021-03-15 **CO 2021-02-16 CO 2021-02-09 IN 2021-03-11 CO 2021-03-18**

 1.0

